Icon
+91 94997 68112
Login Register

Zyclara - (3.75%; Cream, Topical)

IMIQUIMOD MEDICIS Pharmaceuticals
3.75%; Cream, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
None None
Less Than 5
Less Than 5
Indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults
Yes
******* ** *** *** *** ******* ******* *** ********** **** ******* ** ******* ********* ** *** ***** ** ***** ******* *** ****** ** *** *, ****. **** ***** **** ***** * **** ** **** ******* ‘*** (*** **, ****), ‘*** **** **, ****), ‘*** (****** **, ****) *** *** *********. ****** *** ****** ** ** ****** ****, ********** *** ******* **** **** ** ****, ***** *** ***** ** ********** *** *** ***** *** ** ****** **** ** ****** *** ****** ***** *******. ********** **** **** ***** ** **** *** *******, ***** ** ****** ** ********* ** ****'* **** ** ** **********. **** ******** *** **** ** ** *****'* ****** **** ******** ****.
Zyclara Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
******* ******* ******* ******* ******* ******* *******
*** (****) ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** *, **** ******* **** ****** **** ********
*** (****) ** \ ** *** **, **** ******* ******** ******** ** *** **, ****
  1. *** **, **** : ******* ******** ******* ***** *** **** ** **** ****** ‘*** (*** **, ****).
  2. *** **, **** : ******* ***** * **** ******* ******* ** ******** ***** ** ********.
  3. *** **, **** : ******* *** ******* ******* * ********** ********* ** *** ***** ** ***** ******* **** ****** ******* ******* ** *** ********* ** **** *** **** *** ******* ** *******.
  4. *** **, **** : **** ******** ******* ***** *** **** ** **** ******* ‘*** (*** **, ****), ‘*** **** **, ****), ‘*** (****** **, ****).
  5. *** **, **** : ******* ***** * **** ******* **** ** ******** ***** ** ********.
  6. *** *, **** : ********** *** ******* **** *** (****) ***** *** ***** ** ********** *** *** *****.
  7. *** **, **** : ********* *************** ******** ******* *******(*.**% *****) ** **

Zyclara - (2.5% ; Cream, Topical)

IMIQUIMOD MEDICIS Pharmaceuticals
2.5% ; Cream, Topical
Less Than $1000 mn
None None
None None
None None
Indicated for the topical treatment of clinically typical,l nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults
Yes
Zyclara Patent 1
** *******
  1. *** **, **** : * **** ** ** ***** *** ******* ** ******* *** *******

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.